Randomized clinical trial of adjuvant chemotherapy after resection of non-small-cell lung cancer

概要

論文の詳細を見る
The purpose of this trial was to investigate the impact of systemic combination chemotherapy on survival and recurrence after complete resection of non-small-cell lung cancer. Adjuvant therapy was assigned randomly in the 3rd to 4th postoperative week, 34 patients were to receive chemotherapy (treated), while 34 patients were to receive no adjuvant therapy (controls). Chemotherapy consisted of CAPM (cisplatin + adriamycin + cyclophosphamide + mitomycin C) in 14 patients, PAP (cisplatin + adriamycin + peplomycin) in eight patients and PV (cisplatin + vindesine) in 11 patients. PAP treatment was performed only for squamous cell carcinoma. There were 10 recurrences in the treated patients and 9 in the controls. The survival rate after four years was 67. 2% in the treated patients and 78. 4% in the controls, not a significant difference. In addition, analysis of the sites of recurrence showed no significant difference between the two groups. These studies indicate that postoperative chemotherapy offers no benefit in favor of survival or prevention of recurrence of disease.
特定非営利活動法人日本呼吸器外科学会の論文